New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

Expert Rev Pharmacoeconomics Outcomes Res. 2008;8(1):33-42. Human inhaled insulin powder (HIIP) is a dry-powder inhaled insulin product, in which regular insulin is captured in large porous ...

Purpose: Pharmacokinetic and safety data related to the use of inhaled insulin for the management of diabetes mellitus are discussed. The various pulmonary insulin delivery systems under ...

Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

US biotech Dance Biopharm is to work with Phillips-Medisize, to develop a version of its inhaled insulin device that has data connectivity for better management of diabetes treatment. Inhaled ...

After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

The U.S. Food and Drug Administration has approved inhalable insulin to help patients control their blood sugar levels. ManKind Corporation's Afrezza is a fast-acting form of insulin intended for ...

If a person has Medicare Part D, this part may also cover them for diabetes-related supplies, including inhaled or injectable insulin if they do not use an insulin infusion pump. A diabetes ...

I am once again making MannKind Corp. (MNKD) my "Top Pick" for more aggressive investors in 2025, advises Nate Pile, editor of Nate’s Notes.